Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) fuels research, funds innovation, and drives global collaboration to fight pancreatic cancer.
Joined February 2025
- Tweets84
- Following78
- Followers97
- Likes18
Before it was a pill, daraxonrasib was an idea.
We’re proud of our Scientific Advisory Board members’ role in moving that work forward.
The $1M Stephenson Global Prize and our Global Scholar Grans fund ambitious pancreatic cancer research.
Learn more: SGPCRI.org
Long before a breakthrough changes care, it begins in the lab.
Today’s experiments are building the knowledge that could shape tomorrow’s pancreatic cancer treatments.
If you could ask the world’s leading pancreatic cancer researchers one question, what would it be?
Pancreatic cancer research is built on precision.
Every sample prepared, variable controlled, and result recorded helps researchers better understand how the disease behaves and where it may be vulnerable.
Which part of pancreatic cancer research are you most curious about?
This is what it looks like when a room full of people leans into what’s possible.
What had the room so captivated? Get to know Dr. Shokat and the work behind the $1 million Stephenson Global Prize: sgpcri.global/1-million-step…
SGPCRI retweeted
For decades, KRAS was considered “undruggable.” Scientists were even warned that pursuing it was career suicide. UCSF researchers kept going. Their discovery of a hidden pocket helped launch a new class of cancer drugs. ucsf.edu/news/2026/09/432706…
For Emmet Stephenson, this mission is personal.
He lost his wife, Toni, to pancreatic cancer. The Stephenson Global Prize honors her and aims to give more families time together. Together with our Scholar Grants, it helps turn discoveries into treatments.
SGPCRI retweeted
UCSF’s Kevan Shokat, PhD, just won the $1M Stephenson Global Prize for research in pancreatic cancer. He cracked KRAS, a cancer driver long considered “undruggable.” Drugs built on his work now treat lung and pancreatic cancer. ow.ly/xVlw50ZRSXh
ALT Middle-aged man in a blue lab coat smiling while seated in a scientific laboratory setting.
ALT Hand wearing black glove holding five small glass vials with various colored liquids, including pink and orange hues.
SGPCRI retweeted
Phenomenal talk by @kevansf at #AACRpan26 describing the journey to successfully targeting RAS. Well deserved honor from @sgpcri 💜
Congratulations to the pioneer who started it all with his momentous discovery that mutant KRAS in cancer can be directly targeted and blocked:
@kevansf @UCSFCancer on winning the @sgpcri Global Prize!
KRAS inhibitors for the win!
#AACRPan26
SGPCRI retweeted
#AACRFellows Kevan M. Shokat, PhD, FAACR was presented with the 2026 Stephenson Global Prize for research in pancreatic cancer and delivered his award lecture this afternoon during the AACR Conference on Pancreatic Cancer.
#AACRpan26 @sgpcri
The Stephenson Global Prize will be awarded TODAY 🏆
10:30 AM PT / 1:30 PM ET
Watch the announcement live 👇
m.youtube.com/watch?v=jYe1gx…
The next generation of pancreatic cancer researchers is already in the field. Whether they stay may depend on funding.
Every researcher we lose could mean a breakthrough lost with them.
Your gift could keep the right mind in this fight. Will you?
Can fighting pancreatic cancer mean looking beyond the tumor itself?
Stephenson Scholar Liyuan (Liam) Ma, Ph.D., is exploring how boosting “bystander” T cells could break down tumor defenses and activate the body’s own cancer-fighting cells.
What if pancreatic cancer is hiding targets we haven’t been looking for?
Stephenson Scholars William Freed-Pastor, M.D., Ph.D., and Jenn Abelin, Ph.D., are uncovering hidden “flags” that could help advance off-the-shelf vaccines and T-cell therapies.
To outsmart pancreatic cancer, we first need to understand how it adapts.
Stephenson Scholar Tuomas Tammela, M.D., Ph.D., is studying aggressive cancer cell states that help tumors resist therapy, searching for vulnerabilities that could lead to more effective treatments.
Pancreatic cancer tumors may have found a way to shut T cells out. Dr. Koide’s team is working to open the door.
Stephenson Scholar Shohei Koide, Ph.D., is developing antibodies targeting LCN2, a protein that helps keep cancer-fighting T cells from reaching tumors.
Most pancreatic precancers never become cancer. So what makes some turn dangerous?
Stephenson Scholars Marina Pasca di Magliano, Ph.D., and Laura D. Wood, M.D., Ph.D., are studying K17-positive precancers to identify which are most likely to progress and how to stop them.
A new chapter in pancreatic cancer treatment starts today.
The FDA has approved daraxonrasib, expanding treatment options for patients with metastatic pancreatic cancer.
A win for patients, families and researchers.
bit.ly/4qGPNJJ
#PancreaticCancer
